Executive Chairman Fahs L. Reade of National Vision Holdings (NASDAQ: EYE) executed a planned sale of 11,672 shares of common stock on March 6, 2026, receiving approximately $345,217 in proceeds. The dispositions were carried out in multiple trades at prices ranging from $29.57 to $29.58. The sales were made pursuant to a Rule 10b5-1 trading arrangement that Reade established on December 4, 2025.
Concurrent with the share sales, Reade exercised 54,824 restricted stock units on the same date. To satisfy tax withholding obligations associated with those exercises, the company withheld 24,419 shares, representing a withholding value of $681,290. In addition to the exercise, Reade received 71,685 restricted stock units that vest annually on each anniversary of the grant date, beginning March 6, 2026.
Following these transactions, Reade's reported holdings include 694,880 shares held directly and an additional 359,359 shares owned indirectly through a trust.
Market context and valuation
National Vision's shares have risen sharply over the last year, appreciating about 129 percent and trading near a 52-week high of $30.02 at the time of the transactions. InvestingPro's analysis cited in conjunction with these developments indicates the stock remains slightly undervalued relative to its Fair Value. The company carries a market capitalization of approximately $2.13 billion.
Operational and analyst backdrop
Recent company results have outperformed expectations on both earnings and revenue, according to the reporting included with the transaction disclosure. Management has been credited with improved gross margins and tighter expense control. The company has posted four consecutive quarters of positive comparable store sales growth, a trend that reportedly continued into the first quarter despite tougher year-over-year comparisons.
Analysts have generally responded favorably to the company's recent performance. Jefferies, UBS, Guggenheim, Roth/MKM and BofA Securities have retained Buy ratings on the stock. Several firms adjusted price targets in response to the results - Jefferies to $40, UBS to $42 and Guggenheim to $33. Roth/MKM reiterated a $39 target, while BofA Securities maintained a $35 target and projected 2026 earnings per share of $0.94, which aligns with company guidance.
Interpretation and next steps for investors
The insider sale was executed under a pre-established trading plan and coincided with a routine exercise of equity compensation and the issuance of additional RSUs. The firm's recent operational momentum and multiple buy-side analyst recommendations are noted alongside the insider activity. Investors seeking deeper analysis can consult National Vision's dedicated Pro Research Report, which is available for this company and many other U.S. equities through the referenced research service.